It has been reported that serum FGF21 and hepatic mRNA expression levels in patients with NAFLD are significantly higher than levels in control subjects, which correlates with a substantial increase in liver triglyceride levels [14–16]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.